The Lancet Infectious Diseases· Kang Chang, Yimin Wang, Chengmou Wang, Zhengang Tang, Jiangliu Yin, Jiankang Zhao, Yeming Wang, Tao Mei, Aimin Li, Hui Li, Qiuhua Jiang, Peifu Wang, Feng Ye, Lianshu Ding, Zengqiang Liu, Feng Yin, Xueliang Mo, Hongtao Qu, Ying Xia, Jiyue Wang, Jian Wu, Shaochun Yang, Ruisheng Lin, Guangyu Lv, Honghai Luo, Bin Liu, Jiyong Gu, Feng Wei, Junchen Zhu, Honglei Liang, Sheng Qiu, Hui Mai, Xingen Zhu, Rutong Yu, Guangkui Han, Tianzheng Lou, Hongqin Wang, Jinxin Zhang, Yuping Li, Honghao Wang, Hua Lu, Tao Xin, Chen Li, Xun Wang, Xinding Zhang, Heng Gao, Huaxue Wang, Aijun Pan, Qinghua Wang, Jing Cao, Yingqun Zhu, Zuke Xiao, Lei Pan, Shaopeng Peng, Xinmin Ding, Qiong Chi, Hongyang Xu, Fengming Liu, Aihong Guo, Jian Zhan, Qi Zhang, Ruizhong Guo, Toan Huynh, Isaac Biney, Kenneth E Remy, Angela Cano Yuste, Jianguo Li, Dongrun Zhu, Hui Zhao, Bin Cao·· 2 小时前精选AI 评分62
III期试验显示亚胺培南–西司他丁–funobactam治疗医院获得性或呼吸机相关细菌性肺炎达到非劣效
[Articles] Imipenem–cilastatin–funobactam versus imipenem–cilastatin–relebactam in patients with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia: a phase 3, double-blind, non-inferiority randomised trial
AI 导读
一项III期双盲随机非劣效临床试验显示，在医院获得性细菌性肺炎（HABP）及呼吸机相关细菌性肺炎（VABP）患者中，亚胺培南–西司他丁–funobactam在14天全因死亡率方面统计学上非劣于亚胺培南–西司他丁–瑞来巴坦（imipenem–cilastatin–relebactam）。
推荐理由
这项头对头试验以14天全因死亡率评估非劣效性，为医院获得性及呼吸机相关细菌性肺炎的抗菌治疗提供比较证据。
来源：The Lancet Infectious Diseases · thelancet.com